A detailed history of Allworth Financial LP transactions in Incyte Corp stock. As of the latest transaction made, Allworth Financial LP holds 290 shares of INCY stock, worth $23,878. This represents 0.0% of its overall portfolio holdings.

Number of Shares
290
Previous 462 37.23%
Holding current value
$23,878
Previous $28,000 32.14%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$57.33 - $68.61 $9,860 - $11,800
-172 Reduced 37.23%
290 $19,000
Q2 2024

Jul 23, 2024

BUY
$51.18 - $63.75 $2,098 - $2,613
41 Added 9.74%
462 $28,000
Q1 2024

Apr 25, 2024

SELL
$56.55 - $66.59 $21,545 - $25,370
-381 Reduced 47.51%
421 $23,000
Q4 2023

Jan 24, 2024

BUY
$52.16 - $64.19 $11,944 - $14,699
229 Added 39.97%
802 $50,000
Q3 2023

Oct 31, 2023

BUY
$57.77 - $65.93 $7,683 - $8,768
133 Added 30.23%
573 $33,000
Q2 2023

Jul 18, 2023

SELL
$60.95 - $75.51 $17,066 - $21,142
-280 Reduced 38.89%
440 $27,000
Q1 2023

Apr 18, 2023

BUY
$70.23 - $86.01 $1,615 - $1,978
23 Added 3.3%
720 $52,000
Q4 2022

Jan 13, 2023

SELL
$67.18 - $84.11 $2,216 - $2,775
-33 Reduced 4.52%
697 $0
Q3 2022

Oct 18, 2022

BUY
$66.18 - $82.86 $2,250 - $2,817
34 Added 4.89%
730 $49,000
Q2 2022

Jul 13, 2022

BUY
$66.18 - $83.18 $3,441 - $4,325
52 Added 8.07%
696 $53,000
Q1 2022

Apr 22, 2022

BUY
$66.02 - $79.71 $198 - $239
3 Added 0.47%
644 $51,000
Q4 2021

Jan 21, 2022

BUY
$63.34 - $74.11 $18,241 - $21,343
288 Added 81.59%
641 $47,000
Q2 2021

Aug 02, 2021

BUY
$79.87 - $87.53 $28,194 - $30,898
353 New
353 $30,000
Q2 2018

Aug 08, 2018

SELL
$60.85 - $83.98 $60,850 - $83,980
-1,000 Closed
0 $0
Q2 2017

Aug 07, 2017

BUY
N/A
1,000
1,000 $126,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $18.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.